Immunic Inc (IMUX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.11+2.74%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
Immunic is advancing clinical trials with strong product progress. It aims to raise $400 million to fund operations. New leadership may improve strategy and execution. The company targets a net loss per share of $1.08 in 2026.
The company is loss-making with worsening EPS guidance. Leadership changes have been volatile. Litigation and earnings misses pose risks. Revenue remains minimal with uncertain growth.
The stock trades about 19% below our fair value of $19, reflecting skepticism on turnaround success. The market expects continued losses and limited near-term revenue growth.
Breaks if: capital raised falls significantly below $400 million by 2026-Q1
Continue capital raising efforts via private placement to secure up to $400 million in gross proceeds to support operations and development.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is focused on advancing its clinical trials while facing significant financial losses and management volatility.
The market appears to have low expectations for IMUX, given its current loss-making status and weak recent performance. There is little indication of fragility in the stock, suggesting that the market is not overly sensitive to negative news at this time.
Fundamentals are likely to remain weak in the near term, especially with ongoing net losses and negative cash flow. The company's focus on advancing its clinical trials and raising capital may provide some support, but execution risks remain high.
The long-term thesis hinges on successful clinical trial outcomes and the ability to raise necessary capital. Additionally, broader sector momentum and the performance of leading healthcare companies could influence IMUX's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company advanced its MS drug toward key Phase 3 data. However, a sharp drop in the stock price may indicate a repricing of the thesis. This suggests the market is reassessing the reasons to own IMUX.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: further CEO or key leadership departures before end of 2026
Breaks if: net loss per share worsens beyond -1.08 USD in FY26
Control operating losses and improve earnings per share in line with management's guidance for 2026.
Stated as a priority in 3 of last 3 quarters. Management guided to a net loss per share of $(1.08) for 2026. Actual diluted EPS was -1.08 in 2026-Q1 and improved to -0.8 in 2026-Q2, while net income remained negative and operating losses persisted. The trajectory shows limited progress with ongoing losses consistent with clinical-stage biotech operations.
“Diluted EPS was -0.8 and net income was -$34.1 million.”
“Diluted EPS was -1.08 and net income was -$32.6 million.”
“Net income was -$19.3 million and operating income was -$23.3 million.”
In the next 1 to 3 years, IMUX faces significant challenges but also potential opportunities if it can execute on its clinical and financial goals. Not investment advice.